PATENT CLAIM ANALYSIS

Application Number: 16105203
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["435", "194000"]

Abstract:
The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.

Claim (Index 3):
The nucleic acid of  claim 1 , wherein the targeting moiety of the fusion protein is located between the non-cytotoxic protease and the translocation domain and the first protease cleavage site is further located between the non-cytotoxic protease and the targeting moiety.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 96.0
- Lexical Diversity: 1.60465
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14117286', '13774587', '12862948', '13738235', '13239573']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6545892164744548
- 35 USC 102 Novelty (BERT): 0.5799214428464788
- Combined Prediction Score: 0.6471224391116572
- Mean Citation Score: 420.549464
- Max Citation Score: 466.78696
- Similarity Product: 434.3378796947384

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test